Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis

Gut

Volumn 59, Issue 7, 2010, Pages 918-925

  West, Nicholas J ^a   Clark, Susan K ^a   Phillips, Robin K S ^a   Hutchinson, John M ^b   Leicester, Roger J ^c   Belluzzi, Andrea ^d   Hull, Mark A ^b  

^a ST MARK S HOSPITAL   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c ST GEORGE S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ICOSAPENTAENOIC ACID; PLACEBO;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADENOMA; ADENOMATOUS POLYP; ADULT; AGED; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLON RESECTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOSCOPY; EPIGASTRIC DISCOMFORT; FAMILIAL ADENOMATOUS POLYPOSIS; FATTY ACID ANALYSIS; FEMALE; GAS CHROMATOGRAPHY; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALAISE; MALE; MASS SPECTROMETRY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM POLYP; SCORING SYSTEM; VIDEOENDOSCOPY;

ADENOMATOUS POLYPOSIS COLI; ADOLESCENT; ADULT; AGED; ANTICARCINOGENIC AGENTS; COLECTOMY; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; EICOSAPENTAENOIC ACID; FATTY ACIDS; FEMALE; HUMANS; INTESTINAL MUCOSA; INTESTINAL POLYPS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RECTAL NEOPLASMS; SIGMOIDOSCOPY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77953969298     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2009.200642     Document Type: Article

References (40)

1. Edlich R, Cross CL, Wack CA, et al. Revolutionary advances in the diagnosis and treatment of familial adenomatous polyposis. J Environ Pathol Toxicol Oncol 2009;28:47-52.
2. Vasen HFA, Möslein G, Alonso A, et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 2008;57:704-13.
3. Rex DK, Johnson DA, Anderson JC, et al. American College of Gastroenterology. American College of Gastroenterology guidelines for colorectal cancer screening 2009. Am J Gastroenterol 2009;104:739-50.
4. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-16.
5. Steinbach G, Lynch PM, Phillips RKS, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52.
6. Higuchi T, Iwama T, Yoshinaga K, et al. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin Cancer Res 2003;9:4756-60. (Pubitemid 37323278)
7. Farkouh ME, Greenberg BP. An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Cardiol 2009;103:1227-37.
8. Calder PC, Yaqoob P. Omega-3 polyunsaturated fatty acids and human health outcomes. Biofactors 2009;35:266-72.
9. Calviello G, Serini S, Piccioni E. n-3 polyunsaturated fatty acids and the prevention of colorectal cancer: molecular mechanisms involved. Curr Med Chem 2007;14:3059-69.
10. MacLean CH, Newberry SJ, Mojicar WA, et al. Effect of omega-3 fatty acids on cancer risk: a systematic review. JAMA 2006;295:403-15.
11. He K, Rimm EB, Merchant A, et al. Fish consumption and risk of stroke in men. JAMA 2002;288:3130-6.
12. Lawson LD, Hughes BG. Human absorption of fish oil fatty acids as triacylglyercols, free acids or ethyl esters. Biochem Biophys Res Commun 1988;152:328-35.
13. Fini L, Piazzi G, Ceccarelli C, et al. Highly purified eicosapentaenoic acid acts as a potent COX-2 inhibitor and represses polyp formation in APC MIN/+ mice [abstract]. Gastroenterology 2009;136(Suppl 1):A761-2.
14. Paulsen JE, Elvsaas I-K, Steffensen I-L, et al. A fish oil-derived concentrate enriched in eicosapentaenoic and docosahexaenoic acid as ethyl ester suppresses the formation and growth of intestinal polyps in the Min mouse. Carcinogenesis 1997;18:1905-10.
15. Min/+ mice. J Nutr 2000;130:1153-8.
16. Minoura T, Takata T, Sakaguchi M, et al. Effect of dietary eicosapentaenoic acid on azoxymethane-induced colon carcinogenesis in rats. Cancer Res 1988;48:4790-4.
17. Courtney ED, Matthews S, Finlayson C, et al. Eicosapentaenoic acid (EPA) reduces crypt cell proliferation and increases apoptosis in normal colonic mucosa in subjects with a history of colorectal adenomas. Int J Colorectal Dis 2007;22:765-76.
18. Belluzzi A, Brignola C, Campieri M, et al. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med 1996;334:1557-60.
19. Hillier K, Jewell R, Dorrell L, et al. Incorporation of fatty acids from fish oil and olive oil into colonic mucosal lipids and effects upon eicosanoid synthesis in inflammatory bowel disease. Gut 1991;32:1151-55.
20. Latorre A, Rigol A, Lacorte S, et al. Comparison of gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry for the determination of fatty and resin acids in paper mill process waters. J Chromatogr A 2003;991:205-15.
21. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-84.
22. Arber N, Eagle CJ, Spicak J, et al. A randomized controlled trial of celecoxib for prevention of sporadic adenomatous polyps (PreSAP). N Engl J Med 2006;355:885-95.
23. Baron JA, Sandler RS, Bresalier RS, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006;131:1674-82.
24. Phillips RKS, Wallace MH, Lynch PM, et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002;50:857-60.
25. Anti M, Armelao F, Marra G, et al. Effects of different doses of fish oil on rectal cell proliferation in patients with sporadic colonic adenomas. Gastroenterology 1994;107:1709-18.
26. Jump DB. The biochemistry of n-3 polyunsaturated fatty acids. J Biol Chem 2002;277:8755-8.
27. Arterburn LM, Bailey Hall E, Oken H. Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am J Clin Nutr 2006;83(Suppl):1467S- 76S.
28. Pawlosky RJ, Hibbeln JR, Lin Y, et al. Effects of beef- and fish-based diets on the kinetics of n-3 fatty acid metabolism in human subjects. Am J Clin Nutr 2003;77:565-72.
29. Chapkin RS, McMurray DN, Lupton JR. Colon cancer, fatty acids and anti-inflammatory compounds. Curr Opin Gastroenterol 2007;23:48-54.
30. 2 synthesis and cytotoxicity in human colorectal carcinoma cell lines. Carcinogenesis 2003;24:385-92.
31. Boudreau MD, Sohn KH, Rhee SH, et al. Suppression of tumour cell growth both in nude mice and in culture by n-3 polyunsaturated fatty acids: mediation through cyclooxygenase-independent pathways. Cancer Res 2001;61:1386-91.
32. Wada M, DeLong CJ, Hong YH, et al. Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicospentaenoic acid-derived substrates and products. J Biol Chem 2007;282:22254-66.
33. 3 from eicosapentaenoic acid in human lung cancer cells. J Lipid Res 2004;45:1030-9.
34. 3. Carcinogenesis 2008;29:790-6.
35. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999;354;447-55.
36. Cairns JA, Gill J, Morton B, et al. Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. Circulation 1996;94:1553-60.
37. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila Pa) 2009;2:310-21.
38. Vaithianathan R, Hockey PM, Moore TJ, et al. Iatrogenic effects of COX-2 inhibitors in the US population: findings from the Medical Expenditure Panel Survey. Drug Saf 2009;32:335-43.
39. Lavie CJ, Milani RV, Mehra MR, et al. Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol 2009;54:585-94.
40. Thorngren M, Gustafson A. Effects of 11-week increase in dietary eicosapentaenoic acid on bleeding time, lipids, and platelet aggregation. Lancet 1981;318:1190-3. (Pubitemid 12228352)